Results 331 to 340 of about 691,603 (403)

Partial Splenic Embolization for Portal Hypertension Before Radical Nephrectomy in Renal Cell Carcinoma Patient: A Case Report

IJU Case Reports, EarlyView.
ABSTRACT Introduction Partial splenic embolization is a valuable option to manage hypersplenism and reduce portal pressure while preserving splenic function. It may improve surgical safety in patients with portal hypertension. Case Presentation A 67‐year‐old Japanese male with renal cell carcinoma and hepatitis B‐related liver cirrhosis presented with ...
Shunsuke Watanabe, Keita Tamura, Kyohei Watanabe, Yuto Matsushita, Hiromitsu Watanabe, Daisuke Motoyama, Teruo Inamoto   +6 more
wiley   +1 more source

Motor performance as a predictor of blood levels of ammonia and inflammatory biomarkers in patients with liver cirrhosis. [PDF]

PLoS One
San Martín Valenzuela C, Gallego JJ, Urios A, Correa-Ghisays P, Tabares-Seisdedos R, Montoliu C.   +5 more
europepmc   +1 more source

In Vitro Assessment of Drug‐Induced Liver Injury Using Three‐Dimensional Cultured HepaSH Cells Derived From Chimeric Mouse Model With Humanized Liver

Journal of Applied Toxicology, EarlyView.
ABSTRACT Drug‐induced liver injury (DILI) is a serious adverse event and a common cause of postmarketing drug withdrawal. Despite nonclinical assessments of DILI risk, which are predominantly conducted in experimental animals, DILI remains a frequent adverse event, highlighting the need to improve nonclinical assessments.
Xingming Liu, Yuichiro Higuchi, Yuta Sakamoto, Shota Yanagida, Shotaro Uehara, Hiroshi Suemizu, Yasunari Kanda, Hiroyuki Kawagishi   +7 more
wiley   +1 more source

A Case of a Young Pregnant Patient With Congenital Portal Vein Stenosis, Portal Hypertension, and Liver Cirrhosis. [PDF]

Cureus
Alzain FA, Alolaian RJ, Alolayan AJ, Alolaian AJ, Albadrani YH.   +4 more
europepmc   +1 more source

Pharmacokinetics and Safety of Fezolinetant in Women with Hepatic or Renal Impairment

The Journal of Clinical Pharmacology, EarlyView.
Abstract The neurokinin 3 receptor antagonist fezolinetant is an approved treatment for vasomotor symptoms due to menopause. The impacts of hepatic and renal impairment on the pharmacokinetics and safety of a single oral dose of fezolinetant 30 mg were investigated in two independent studies.
Megumi Iwai, Xuegong Wang, Melanie Patton, Lauren Benner, Nakyo Heo, Jace C. Nielsen, Anna Spence, Thomas C. Marbury, Jiayin Huang   +8 more
wiley   +1 more source

Skeletal muscle abnormalities negatively linked to sleep disturbances in patients with liver cirrhosis: a cross-sectional study. [PDF]

Eur J Med Res
Yao S, Peng B, Liu W, Yang J, Hui Y, Sun C.   +5 more
europepmc   +1 more source

Saliva as a TDM matrix and its application in the model‐informed precision dosing

The Journal of Clinical Pharmacology, EarlyView.
Abstract This study reviews the main points of saliva as a therapeutic drug monitoring (TDM) matrix, its advantages and limitations, the methods of saliva sample collection and testing, the types of drugs in saliva TDM, and the methods of establishing saliva population pharmacokinetic (Pop PK) models, as well as summarizes the experiences and ...
Baohua Xu, Yujie Wen, Jinxia Lu, Maobai Liu, Xin Luo, Wei Huang, Helin Xie, Yu Cheng, Hongqiang Qiu, Xuemei Wu   +9 more
wiley   +1 more source

Paroxysmal nocturnal hemoglobinuria revealed by atypical thromboses: A case of cerebral, hepatic, and portal vein involvement leading to cirrhosis. [PDF]

Radiol Case Rep
Malghi M, Zouaoui M, Bamaarouf I, Messaoudi S, Hnach Y, Azouaoui M, Aqodad N.   +6 more
europepmc   +1 more source

Recent Utilization of Pediatric Extrapolation and Modeling and Simulation Approaches in Pediatric Drug Development in Japan

The Journal of Clinical Pharmacology, EarlyView.
Abstract In Japan, the percentage of approved drugs with pediatric indications increased to 30% in 2010‐2015, but no further increase was observed through 2020. The Ministry of Health, Labor, and Welfare in Japan presented draft future directions to promote pediatric drug development, where the modeling and simulation (M&S) approach was introduced as a
Akinori Nakashima, Akihide Tsujimoto, Masako Saito, Jun Takeda, Makiko Natori, Satoshi Shoji   +5 more
wiley   +1 more source